Contribute Try STAT+ Today

The Food and Drug Administration on Monday approved Biogen’s new Alzheimer’s drug, a decision with far-reaching implications for patients, clinicians, and others. Here’s a rundown on some basic questions and answers about the drug, known as Aduhelm.

Who can get the drug?

The drug, tested in patients with mild cognitive impairment, is approved for patients with Alzheimer’s. They will need an MRI within one year of starting treatment and will also have to undergo more MRIs during treatment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • 40% of clinical trial patients had painful brain swelling, and 17-18% had micro-hemorrhages in the brain?? Drugs with such inherent high risk of stroke, or at minimum further brain deterioration, and based on an amyloid plaque theory that has been debunked in so many other trials – this would normally not be approved by the FDA. What is happening there? Who is paying who, to push such a very questionable drug so un-restricted??

  • It is obscene to charge $56,000 per year for a drug that doesn’t improve cognitive ability

  • Joanna Panzera said “I have often thought maybe we should experiment with ketamine infusion therapy to treat Alzheimer’s disease since it helps create new neuro pathways in the brain. I remember the first time I thought of this was when I was told that a person who does the same thing every day is much more likely to develop Alzheimers. Maybe its because they are reinforcing the same neuro pathway over and over again.”

  • This is very high priced for something that is not even determined if it actually is helping, when there are studies already out there that have not even been human tested that have brought forth remarkable results in lab rats.

    A molecule called ISRIB (Integrated Stress Response InhiBitor) releases the brakes to reboot protein production. When tested in traumatic brain injury (TBI), ISRIB’s results were remarkable. The license for this is owned by Google’s own Calico labs. They have been sitting on this for some time and because they are so secretive about their work, no one knows if they are going to pursue it or not. It has been around for several years now.

  • Many patients have been waiting for years for Emeramide approval from FDA, with a strong benefit and safety profile for treating mercury toxicity, more common than many know – a toxic element that doesn’t do any favors to the brain and memory.

  • Sent to my parents: I don’t recommend the new “adu” drug, FYI. As measured by tests of cognition and function, the difference between aducanumab and placebo was a fraction of a point on an 18-point scale. Almost any other intervention would be better value.

  • How soon can Aduhelm be administered to a patient now that it’s been approved?

  • I think there is compelling evidence that Alzheimer’s is a result of infection. Leaky gut and persistent infections (latent, probably) seem to be the most likely sources.
    The theory goes that amyloid is a defense to the infection(s). And if you have the gene, your defense is a bit more aggressive.
    I think we need to go after these infections. Kill the pathogens and heal the gut.
    Yes, exercise seems to help and the mind diet, but I think we can do a lot more. I think that our modern diets are low in glycine and proline because we typically don’t eat anything from an animal except the muscle. Gelatin contains these components. I think the health effects of gelatin in regard to cognitive decline and brain aging diseases needs to be investigated. Vegetarians can eat lots of Pumpkin Seeds instead, as they also have glycine and proline.
    And we need to try killing/deactivating pathogens, even if their low level infections have not been considered serious in the past.
    Maybe after the infections are cured, and the gut is healed, it will be safe to remove the amyloid. Without taking care of the underlying problem, I don’t have a lot of faith in this treatment or other amyloid removers.

    • Do you think its possible that Amyloid can build up the same way “fuzz” forms on the sliding surfaces of muscles from lack of movement? Can treating patients intravenously with ketamine melt the fuzz in a sense by creating a new neuro pathway hense melting it away in order to form it? I don’t know if this makes sense to a doctor. I haven’t studied what you have its just a thought though. I also agree healing leaky gut should be researched more in regards to Alzheimer treatment.

  • Not sure why anyone would accept the risk vs possible benefit ratio for this new and unproven drug when simply using the organic and proven benefits of 1. Daily exercise 2. Going on the MIND diet 3. Adding needed dietary supplements 4. HBOT, have been proven to help most AD patients stop the progression of the disease as well as reverse many of its symptoms and do so without risk of negative side effects.

Comments are closed.